TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04033211

Intervention type: DEVICE
Intervention: Novosyn® CHD for fascia and skin closure
Description: Experimental

Intervention type: DEVICE
Intervention: Novosyn® for fascia and skin closure
Description: Comparator
Study: NCT04607421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
Study: NCT00537745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol (Medication Therapy)
Description: Vivitrol 380 mg/monthly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Management Therapy
Description: Medication Management Therapy once a month.
Study: NCT01483092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: 20g/day for 4 weeks
Study: NCT04607421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
Study: NCT01483092

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: 20g/day for 4 weeks
Study: NCT04019496

Intervention type: DRUG
Intervention: antibodies against calcitonin-gene related peptide or its receptor
Description: the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
Study: NCT03291782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: oral, single dose
Study: NCT04607421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
Study: NCT04607421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 150 mg or 500 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Optional Injection for intravenous use 100 mg/vial or 400 mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
Study: NCT03291782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: oral, single dose
Study: NCT03506594

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency non ablative
Description: The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
Study: NCT04042415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction without cow's milk and gluten
Description: Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
Study: NCT03068026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaBreath
Description: The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaBreath
Description: The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
Study: NCT02920567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
Study: NCT00194675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5 mg orally daily
Study: NCT03068026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing technique
Description: Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing technique
Description: Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
Study: NCT01516450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1550188 IV
Description: Single IV dose of belimumab 200 mg
Study: NCT00194675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 7.5 g daily topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 7.5 g daily topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo dutasteride
Description: placebo dutasteride orally daily
Study: NCT05072327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mohs surgery
Description: Mohs surgery of eyelid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mohs surgery
Description: Mohs surgery of eyelid
Study: NCT01516450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1550188 SC
Description: Single SC dose of belimumab 200mg
Study: NCT01819961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT/LCT and fish oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT/LCT
Study: NCT03630068

Intervention type: PROCEDURE
Intervention: Stereotactic percutaneous image-guided microwave ablation
Description: Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
Study: NCT01582724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-care acupressure at three predefined points
Description: Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
Study: NCT01056523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine arabinoside
Description: Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
Study: NCT01954628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Synthetic SHIP1 activator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT00389077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 50 mg tablets
Study: NCT05072327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy of eyelid
Study: NCT01076075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
Study: NCT03656640

Intervention type: DRUG
Intervention: Gammanorm
Description: Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
Study: NCT01823653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposonix System (Model 2)
Description: Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
Study: NCT01520922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
Study: NCT01076075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to pioglitazone
Description: Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo to Sitagliptin
Description: Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride or gliclazide
Description: Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride or gliclazide
Description: Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin
Study: NCT02185170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-urethral resection
Description: All subjects of the study are going to have a trans-urethral resection of prostate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the FEMTO-ST institute medical device
Description: The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Light-CT scanner
Description: The Light-CT Scanner is use in the tissue structural observation
Study: NCT03506672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Approach based on the meanings of vocal behaviours
Description: Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
Study: NCT02920567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
Study: NCT04046952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Statseal with TR Band
Description: Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR band only
Description: Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
Study: NCT01401075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mistletoe extract
Description: subcutaneous injections thrice weekly with 1 ml in 4 increasing doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxifluridine
Description: 600 - 900 mg per day orally, depending on weight and status of the patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxifluridine
Description: 600 - 900 mg per day orally, depending on weight and status of the patient
Study: NCT01076075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone rescue therapy
Description: Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone rescue therapy
Description: Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
Study: NCT02116478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical proximal medial gastrocnemius recession
Description: proximal medial gastrocnemius recession
Study: NCT04971330

Intervention type: DIAGNOSTIC_TEST
Intervention: Access HCV
Description: All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status

Intervention type: DIAGNOSTIC_TEST
Intervention: Access HCV
Description: All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status

Intervention type: DIAGNOSTIC_TEST
Intervention: Access HCV
Description: All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status
Study: NCT03114059

Intervention type: DIAGNOSTIC_TEST
Intervention: Glaucoma diagnostics
Description: Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
Study: NCT04610164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Prior to surgery, the patient will receive 1 gram of IV TXA
Study: NCT04932070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
Study: NCT02663583

Intervention type: BEHAVIORAL
Intervention: Symptom Questionnaires
Description: Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.

Intervention type: BEHAVIORAL
Intervention: Symptom Questionnaires
Description: Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.

Intervention type: BEHAVIORAL
Intervention: Dysphagia Inventory Questionnaire
Description: Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.

Intervention type: BEHAVIORAL
Intervention: Dysphagia Inventory Questionnaire
Description: Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.

Intervention type: BEHAVIORAL
Intervention: Activity Bands
Description: Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.

Intervention type: BEHAVIORAL
Intervention: Activity Bands
Description: Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.